China Approves Oral Orforglipron for Weight Management

China’s regulator approved Lilly’s oral nonpeptide GLP-1 receptor agonist orforglipron calcium for long-term weight management in adults with obesity or overweight plus a weight-related comorbidity. The action establishes a new oral small-molecule option in…




